SSShirin Saberianpour

Shirin Saberianpour

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shirin Saberianpour has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A review of current evidence from cardiovascular manifestations and outcomes in patients with COVID-19

    by Ali Hasanpour-Dehkordi, Shirin Saberianpour, Elahe Aleebrahim-Dehkordi, Elaheh Mazaheri

    Background: In 2019, acute respiratory syndrome related to COVID-19 occurred as a global epidemic problem. The COVID-19 pathogenesis method is by using enzyme 2-converting enzyme angiotensin ACE2, which infects host cells, which is resulted in some organs, involving the lungs, heart, kidneys and intestines According to reports from the first signs of involvement of the cardiovascular system in various forms, the involvement of Cardiovascular injuries. The aim of this study was to evaluate the cardiovascular manifestations in COVID-19 disease. Methods: In this study with help of medical science database (Scopus, PubMed and etc.) for gathering of basic information and recent reports of COVID-19 disease in all over the world. All the data collected from the databases were identified and evaluated so that the evidence could be fully reported and ultimately a general conclusion could be reached. Results: Cardiac complications in patients with COVID-19, could be caused by several mechanisms, some of which overlap, e.g., IL-6 and inflammation. Direct viral cardiomyocyte invasion, with unopposed angiotensin II effects, immune activation, microvascular dysfunction, or increased metabolic demand, could contribute to the to heart damage. Conclusion: COVID-19, in turn, can exacerbate cardiovascular damage Along with other symptoms of for COVID-19. If care services, medical and treatment facilities, as well as the care team provide the required care and treatment in a timely manner, it will lead to the reduction of mortality rate.

  • Open Access

    Autophagy and treatment of patients with COVID-19; which drugs target the autophagy pathway?

    by Elahe Aleebrahim-Dehkordi, Shirin Saberianpour, Ebrahim Soleiman-Dehkordi, Dariush Hooshyar, Zahra Mojtahedi, Neda Kianpour, Ali Hasanpour-Dehkordi, Lillian Saberian, Mohsen Akhavan Sepahi

  • Open Access

    Role of Macrophages in Vascular Regeneration

    by Shirin Saberianpour

    : Angiogenesis is very important for most strategies for regenerative damaged organs. The natural inflammatory response can be affected by the activity of different types of macrophages and their cytokines. Macrophages exist in a wide variety of phenotypes. These macrophages can range from classic M1 to M2 macrophages. M2 macrophages themselves can include different types of subgroups. These types of macrophages are usually effective in vascular regeneration while M1 or classic macrophages play a role in chronic wounds. The macrophages move toward the M2 phenotype or inhibit the polarization of the macrophages toward the M1 phenotype. On the other hand, macrophage polarization can be affected by a variety of factors, such as different types of miRNAs. The process of vascular repair and enhancing the therapeutic potential of drug regulators the treatment of vascular damage through modification of macrophage polarization. Macrophages do this by various mechanisms, which are described in detail in this study. Finally, new therapeutic mechanisms aimed at macrophages in vascular disease are discussed.

  • Open Access

    Acute kidney injury in COVID-19; a review on current knowledge

    by Elahe Aleebrahim-Dehkordi, Ali Reyhanian, Shirin Saberianpour, Ali Hasanpour-Dehkordi

    Coronaviruses are a large family of viruses that can cause a variety of diseases in humans. Some coronaviruses cause only mild illnesses like the common cold. While, some coronaviruses such as SARS-CoV (SARS-associated coronavirus) and Middle East respiratory syndrome coronavirus (MERS-CoV) have, in recent years, been able to cause severe respiratory involvement (pneumonia), leading to death in several patients. By identifying the genomic sequence of the new human coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) it has been revealed that it belongs to the beta coronavirus genus. COVID-19 appears to be transmitted by a mechanism similar to the influenza virus via person to person, sneezing coughing, or contact with the secretions of infected patients. Early symptoms of these respiratory viruses include fever, cough, and shortness of breath, with an incubation period of 2-14 days. SARS-CoV-2 is an acute respiratory disease that initially causes lung damage. SARS-CoV-2 can affect other organs, including the kidneys. Kidney damage may be caused by alterations that occur during coronavirus infection. It seems that low-oxygen delivery to tissues like the kidney in the setting of this disease may lead to ischemic damage of the kidney. Considering the importance of the kidneys, as one, this review study aimed to investigate the effect of the new coronavirus on the kidneys and its role in the development of renal failure.